|
 |
||
      |
|
| » What We Do
» Who We Are - Board of Directors - Scientific Council - National Leadership Council - Leadership Awards - Staff - Contact Us » History & Accomplishments » Financial Information 
|
 Biography   Robert B. Innis, M.D., Ph.D. Chief, Molecular Imaging Branch National Institute of Mental Health Dr. Innis directs in vivo neurochemical imaging with an emphasis on targets relevant to neuropsychiatric disorders. His goal is to develop new radiotracers that image molecular targets in the brain, evaluate them in animals and in healthy human subjects and then extend their use to neuropsychiatric patients. Among the radiotracers he and his group have de-veloped are probes for the dopamine transporter, which is a biological marker for Parkinson's disease. Imaging of the dopamine transporter was recently approved in several European countries to aid in early Parkinson’s diagnosis. At NIMH, where Dr. Innis moved in 2001 after more than two decades at Johns Hopkins University, the technologies he uses are primarily PET (positron emission tomography) and NMR (nuclear magnetic resonance). New PET radiotracers are synthesized to measure many different targets, such as proteins associated with intracellular signal transduction. Earlier in his career, before PET was available, he used SPECT (single-photon emission computed tomography). His benzodiazepine-receptor imaging confirmed SPECT capable of quantitative measurements, studies he then expanded to include serotonin, GABA, acetylcholine and other systems. Dr. Innis joined NARSAD’s Scientific Council in 1996. |
Latest News from NARSAD
Upcoming NARSAD Events
Infoline
|
